High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection

European Journal of Clinical Investigation

Volumn 37, Issue 9, 2007, Pages 724-730

  Hsu, P I ^a,b,d   Lai, K H ^a   Wu, C J ^a   Tseng, H H ^b   Tsay, F W ^a   Peng, N J ^b   Chen, T A ^a   Chuah, S K ^c   Lin, W S ^d   Lo, G H ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Esomeprazole; Helicobacter pylori; Therapy dose

Indexed keywords

AMOXICILLIN; ANTACID AGENT; CLARITHROMYCIN; ESOMEPRAZOLE;

ABDOMINAL PAIN; ADULT; ANALYTIC METHOD; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOSCOPY; ERADICATION THERAPY; FEMALE; GASTRITIS; HEADACHE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; SIDE EFFECT; TAIWAN; TASTE AVERSION; TREATMENT RESPONSE;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34547854335     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01852.x     Document Type: Article

References (33)

1. Hsu PI, Lai KH, Hsu PN, Lo GH, Yu, HC, Chen WC et al. Helicobacter pylori infection and the risk of gastric malignancy. Am J Gastroenterol 2007 102 : 1 6.
2. Go MF. Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002 16 (Suppl. 1 3 15.
3. Uemura N, Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S et al. Helicobacter infection and the development of gastric cancer. N Engl J Med 2001 345 : 784 9.
4. Hsu PI, Lai KH, Lo GH, Tseng HH, Lo CC, Chen HC et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut 2002 51 : 15 20.
5. Hsu PI, Li CN, Tseng HH, Lai KH, Hsu PN, Lo GH et al. The interleukin-1 RN polymorphism and Helicobacter pylori infection in the development of duodenal ulcer. Helicobacter 2004 9 : 605 13.
6. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D et al. Current concept in the management of. Helicobacter infection: the Maastricht III. Gut 2006, doi:10.1136.
7. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of 3 US multicenter, double-blind trials. Am J Gastroenterol 2000 95 : 3393 8.
8. Bytzer P, O'Morain C. Treatment of Helicobacter pylori. Helicobacter 2005 10 (Suppl. 1 40 6.
9. Lamouliatte H, Samoyeau R, De Mascarel A, Megraud F. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999 13 : 1523 30.
10. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002 16 : 1149 56.
11. Spencer C, Faulds D. Esomeprazole. Drugs 2000 60 : 321 9.
12. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole. A review of its use in the management of acid-related disorders. Drugs 2002 62 : 1504 38.
13. Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000 56 : 665 70.
14. Dent J. Pharmacology of esomeprazole and comparisons with omeprazole. Aliment Pharmacol Ther 2003 17 (Suppl. 1 1 4.
15. Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 98 : 2616 20.
16. Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005 100 : 2387 92.
17. Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Esomeprazole vserus omeprazole for the eradication of Helicobacter pylori infection-results of a randomized controlled study. J Clin Gastroenterol 2004 38 : 503 6.
18. Sheu BS, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005 21 : 283 8.
19. Hsu PI, Lai KH, Lo GH. The optimal dose of esomeprazole for anti-Helicobacter pylori therapy. Am J Gastroenterol 2006 101 : 1399.
20. Shimizu T, Ochiai H, Asell F, Shimiru H, Saitoh R, Hama Y et al. Bioinformatics research on inter-racial difference in drug metabolism. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003 18 : 48 70.
21. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000 25 : 197 220.
22. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995 29 : 192 209.
23. Lam SK, Hasan M, Sircus W, Wong J, Ong GB, Prescott RJ. Comparison of maximal acid output and gastric gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. Gut 1980 21 : 324 8.
24. Wu CJ, Hsu PI, Lo GH, Lo CC, Lin CK, Shie CB et al. Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection. J Chin Med Assoc 2004 67 : 161 7.
25. Hsu PI, Lai KH, Tseng HH, Lo GH, Lo CC, Lin CK et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001 15 : 195 201.
26. Lo CC, Lai KH, Peng NJ, Lo GH, Tseng HH, Lin CK et al. Polymerase chain reaction: a sensitive method to detect Helicobacter pylori infection in bleeding peptic ulcers. World J Gastroenterol 2005 11 : 3909 14.
27. Hsu PI, Lai KH, Tseng HH, Liu YC, Yen MY, Lin CK et al. Correlation of serum immunoglobulin G Helicobacter pylori antibody titers with histologic and endoscopic findings in patients with dyspepsia. J Clin Gastroenterol 1997 25 : 587 91.
28. Hsu PI, Lai KH, Chien EJ, Lin CK, Lo GH, Jou JS et al. Impact of bacterial eradication on the cell proliferation and p53 protein accumulation in Helicobacter pylori-associated gastritis. Anticancer Res 2000 20 : 1221 8.
29. Peng NJ, Lai KH, Liu RS, Lee SC, Tsay DG, Lo CC et al. Endoscopic 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Dig Liver Dis 2003 35 : 73 7.
30. Peng NJ, Lai KH, Liu RS, Lee SC, Tsay DG, Lo CC et al. Clinical significance of oral urease in the diagnosis of H. pylori infection by 13C-urea breath test. Dig Dis Sci 2001 46 : 1772 8.
31. Laine L. Esomeprazole in the treatment of Helicobacter pylori. Aliment Pharmacol Ther 2002 16 (Suppl. 4 115 8.
32. Madan A, Holland S, Humbert JE, Benitz WE. Racial differences in birth weight of term infants in a northern California population. J Perinatol 2002 22 : 230 5.
33. Thorpe LE, List DG, Marx T, May L, Helgerson SD, Frieden TR. Childhood obesity in New York City elementary school students. Am J Public Health 2004 94 : 1496 500.